NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-08-31
Reading ELV? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Warn: Management is running behind on a stated commitment.
Elevance Health grows earnings steadily with EPS guidance raised to $26.75 for 2026. The company generates strong cash flow, targeting at least $5.5 billion in operating cash flow. It returns capital consistently, repurchasing $1.1 billion in shares in Q1 2026. Valuation is cheap versus peers, trading at a PE of 13.6 versus 26.6 median.
Revenue growth is weak, with consensus expecting a slight decline of -0.6%. Management guidance is soft, and operating risks like regulatory sanctions could hurt results. Share buybacks may slow if cash flow weakens.
The market prices the stock about 9% below our fair value near $453, reflecting modest revenue decline expectations. Our fair value is 7% above the Street median, indicating some upside if growth stabilizes.
Breaks if: EPS guidance falls below $25.5 for FY 2026
Continue to increase full-year 2026 adjusted diluted EPS guidance reflecting strong operating results and underlying business strength.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a durable compounder with a focus on steady growth. The current thesis state is intact, with recent earnings beats reinforcing confidence despite some mixed management execution.
The market seems to price in a low level of fragility, reflecting a cheap valuation compared to peers. There is a slight expectations gap, indicating that the market may not fully account for the company's potential upside.
Fundamentals are likely to remain strong, as management has consistently raised guidance and reaffirmed operating cash flow targets. However, there is a moderate risk due to recent trends in earnings surprises and potential economic headwinds.
The thesis hinges on management's ability to maintain or raise guidance, as well as the performance of sector bellwethers like UNH, CVS, and CI. Additionally, macroeconomic factors, such as the jobs report, could impact sentiment and performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a more favorable outlook. There are no new threats impacting the thesis at this time.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 5 of last 5 quarters. FY 2026 adjusted diluted EPS guidance was raised from $25.50 in 2025-Q4 to $27.00 in 2026-Q2, reflecting strong operating results and underlying business strength. Management has consistently raised or reaffirmed this guidance, and the trajectory is delivering.
“FY 2026 adjusted EPS guidance raised to at least $27.00, reflecting strong second quarter operating results.”
“FY 2026 adjusted diluted EPS guidance raised to at least $26.75, supported by underlying business strength.”
“Projected FY 2026 adjusted diluted EPS to be at least $25.50.”
“Reaffirm FY 2025 adjusted diluted EPS guidance of approximately $30.00.”
“Revising FY 2025 adjusted diluted EPS to approximately $30.00.”
Breaks if: Operating cash flow falls below $5.0 billion in FY 2026
Breaks if: Revenue growth falls below -1% YoY
Breaks if: Buybacks drop below $0.8 billion per quarter
In the next 1 to 3 years, ELV's performance will depend on continued strong execution and sector momentum. Not investment advice.
